Zepbound Outperforms Wegovy in Weight Loss Trial

By Rene Pretorius

December 6, 2024

The news release from Eli Lilly and Company, titled “Lilly’s Zepbound® (tirzepatide) superior to Wegovy® (semaglutide) in head-to-head trial, highlights the critical comparison of Zepbound vs Wegovy in treating obesity. Zepbound has shown superior efficacy, making it a compelling option for managing weight in adults.

The SURMOUNT-5 trial involved adults living with obesity or overweight with at least one weight-related medical condition but without diabetes. Zepbound outperformed Wegovy on both the primary endpoint and five key secondary endpoints at 72 weeks. The trial demonstrated that Zepbound was superior to Wegovy in terms of weight loss. Participants using Zepbound achieved an average weight loss of 20.2%, compared to 13.7% for those taking Wegovy. In terms of absolute weight loss, those on Zepbound lost 50.3 lbs (22.8 kg), while participants on Wegovy lost 33.1 lbs (15.0 kg). A key secondary endpoint showed that 31.6% of people taking Zepbound achieved at least 25% body weight loss, compared to just 16.1% of those taking Wegovy.

Mechanism of Action – Zepbound vs Wegovy

Tirzepatide, the active ingredient in Zepbound, is a dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptor agonist. In contrast, semaglutide is a mono GLP-1 receptor agonist.

Safety Profile

The overall safety profile of Zepbound in the SURMOUNT-5 trial was similar to previous studies. The most commonly reported adverse events were gastrointestinal-related and generally mild to moderate in severity.

Regulatory and Market Status

Tirzepatide is commercialized as Zepbound for adults with obesity or overweight and weight-related medical problems in some global markets outside the U.S. It received U.S. FDA approval on November 8, 2023, for this indication and is also marketed as Mounjaro for adults with type 2 diabetes.

Ongoing and Future Zepbound Studies

Ongoing studies of tirzepatide focus on its effects in four disease areas. These areas are chronic kidney disease (CKD), morbidity/mortality in obesity (MMO), moderate-to-severe obstructive sleep apnea (OSA), and heart failure with preserved ejection fraction (HFpEF). The data reinforces the efficacy and safety of Zepbound vs Wegovy in managing obesity. Zepbound is a significant treatment option for adults with obesity or those who are overweight and facing related medical challenges.

Reference url

Recent Posts

Mavyret acute hepatitis C
         

Mavyret Acute Hepatitis C: Pioneering Treatment Expansion and Economic Implications

🌟 Did you know that the FDA has just approved the first-ever treatment specifically for acute Hepatitis C?

AbbVie’s Mavyret (glecaprevir/pibrentasvir) is now set to improve the way we think about HCV interventions, enabling earlier treatment to reduce long-term complications and improve patient outcomes. This approval not only addresses an urgent public health need but also aligns with evolving healthcare delivery models focused on cost-effective solutions.

Curious to learn more about the implications of this significant advancement in hepatitis care? Review the full article for insightful analysis on the future of HCV treatment!

#SyenzaNews #HealthcareInnovation #MarketAccess #HealthEconomics

HIV vaccine trials
    

Advancements in HIV Vaccine Trials: Promising Results from mRNA Strategies

🌍 Are we finally making strides in the fight against HIV?

Recent phase 1 vaccine trials using mRNA technology have shown promising results in activating immune responses that could lead to broadly neutralizing antibodies (bnAbs). This innovative approach not only addresses HIV’s rapid mutation but also offers critical insights for high-prevalence regions.

Dive into the full article to explore how these trials could shape the future of HIV prevention and what it means for global health!

#SyenzaNews #globalhealth #HIV #clinicaltrials

EHK clusters 2026 report
       

EHK Clusters 2026 Report: Enhancements in Dutch Risk Equalization for High-Cost Pharmaceuticals

🚀 Are you curious about how the Dutch healthcare system is adapting to high-cost pharmaceuticals?

The latest EHK clusters report for 2026 brings crucial updates to the risk-equalization model, enhancing equity among health insurers while closely managing skyrocketing costs. With innovative clustering techniques and revised reimbursement figures, these changes aim to improve access and accountability in an increasingly competitive healthcare landscape.

Dive into the full article to uncover the implications for health economics and policy!

#SyenzaNews #HealthEconomics #HealthcareInnovation

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.